Kyverna Therapeutics, Inc. Common Stock (KYTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kyverna Therapeutics, Inc. Common Stock (KYTX) has a cash flow conversion efficiency ratio of -0.213x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.60 Million) by net assets ($195.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Kyverna Therapeutics, Inc. Common Stock (KYTX) balance sheet quality index to measure how much of total assets are equity-financed.
Kyverna Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Kyverna Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how well can Kyverna Therapeutics, Inc. Common Stock service its debt to assess how comfortably operating cash covers total debt obligations.
Kyverna Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kyverna Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Doubledown Interactive Co Ltd
NASDAQ:DDI
|
0.044x |
|
Albaraka Turk Katilim Bankasi AS
IS:ALBRK
|
-0.403x |
|
Djurslands Bank
CO:DJUR
|
0.002x |
|
Lendingtree Inc
NASDAQ:TREE
|
0.038x |
|
WIA Gold Ltd
AU:WIA
|
0.000x |
|
Shenzhen Longli Technology Co Ltd Class A
SHE:300752
|
0.018x |
|
Spire Global Inc
NYSE:SPIR
|
0.000x |
|
Jiangsu Hengxing New Material
SHG:603276
|
0.012x |
Annual Cash Flow Conversion Efficiency for Kyverna Therapeutics, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Kyverna Therapeutics, Inc. Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see Kyverna Therapeutics, Inc. Common Stock stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $232.28 Million | $-153.71 Million | -0.662x | -54.41% |
| 2024-12-31 | $266.59 Million | $-114.25 Million | -0.429x | +59.79% |
| 2023-12-31 | $49.18 Million | $-52.41 Million | -1.066x | -37.75% |
| 2022-12-31 | $46.68 Million | $-36.11 Million | -0.774x | -261.52% |
| 2021-12-31 | $-46.25 Million | $-22.16 Million | 0.479x | -- |
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product ca… Read more